MedTech News
.................... by Andrew Celentano
A gut microbe makes a fatty acid that cuts artery plaque in half in mice
A common gut bacterium produces a molecule that slows cholesterol production in the liver. When researchers gave the molecule to mice prone to artery disease, the animals developed roughly half as much fatty plaque as untreated controls.
FDA APPROVES GORE® VIABAHN® VBX BALLOON EXPANDABLE ENDOPROSTHESIS FOR EXPANDED USE IN FEVAR AND BEVAR
FLAGSTAFF, Ariz., Oct. 14, 2026 /PRNewswire/ — W. L. Gore & Associates’ medical business (Gore) today announced U.S. Food and Drug Administration approval of an expanded indication for the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX Stent Graft) for use in fenestrated and branched endovascular aortic repair (FEVAR and BEVAR).
Maverix Medical Expands the Narwhal™ Cryo Portfolio with FDA Clearance of the Narwhal Pro
MENLO PARK, Calif., Oct. 14, 2026/PRNewswire/ — Maverix Medical, a company focused on revolutionizing the diagnosis and treatment of lung cancer, has augmented its console-free cryoprobe portfolio. Today the company announced that the U.S. Food and Drug Administration granted 510(k) clearance on September 2, 2026, to the Maverix Narwhal™ Pro Cryo System, the second of two flexible cryoprobes built on the same cartridge-powered architecture.
Florida Cancer Specialists & Research Institute Contributes to Two Significant FDA Approvals Advancing Breast and Pancreatic Cancer Care
FORT MYERS, Fla., Oct. 14, 2026 /PRNewswire/ — Florida Cancer Specialists & Research Institute, LLC (FCS) is celebrating its pivotal role in the development of two recently approved targeted therapies that expand treatment options for patients with advanced breast and pancreatic cancers, underscoring the FCS’s longstanding commitment to advancing oncology research and expanding access to clinical trials.
Trial Demonstrates Feasibility of At-Home Subcutaneous Diuretic Therapy for Heart Failure-Associated Edema
BURLINGTON, Mass., Oct. 14, 2026 /PRNewswire/ — SQ Innovation today announced that results of the SUBCUT HF II trial of its product Lasix® ONYU have been published in the Journal of the American College of Cardiology (JACC)1, one of the leading peer-reviewed journals in cardiovascular medicine.
AI screening helps more people with diabetes access sight-saving eye care
People receiving AI-supported screening for diabetic retinopathy, a leading cause of blindness globally, were almost twice as likely to attend specialist follow-up appointments as those receiving standard screening, according to new research from the London School of Hygiene & Tropical Medicine (LSHTM).
How a common virus’s hijack of cell repair processes may promote cancer
Most people will become infected with Epstein-Barr virus, or EBV, at some point in their lives. In addition to being a common herpesvirus, EBV persists in its host for life as a “quiet” or latent infection.
Targeted radioactive therapy may help delay spread of recurrent prostate cancer
Adding the targeted radioactive drug 177Lu-PNT2002 to stereotactic body radiation therapy, or SBRT, may help keep recurrent prostate cancer under control longer than SBRT alone, according to new research led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.